CyberKnife radiation for certain pancreatic cancer patients after chemotherapy
Part of Cancer, Digestive system clinical trials.
This trial studies how safe CyberKnife is when used to treat some borderline resectable or locally advanced pancreatic cancers after chemotherapy. It may help patients by targeting the tumor with precise radiation, while researchers closely watch for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are able to sign consent and understand the study steps
- You finished a chemotherapy treatment plan before joining the trial
- You are 18 years or older
- Your general health is good enough (ECOG 0 to 1)
- Your pancreatic cancer is stage I to III and has no spread to distant organs
- Your tumor can be treated with radiation (IMRT or SBRT) and your tumor team agrees
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a procedure called NanoKnife IRE for pancreatic cancer that cannot be removed surgically after standard chemotherapy or radiation. It uses electric pulses to destroy tumor cells and may be an option for patients who have completed other treatments.
This trial tests whether CyberKnife (high-precision radiation) can treat early-stage kidney cancer. It may help people avoid or delay more invasive treatments by targeting the tumor while protecting nearby organs.
This trial tests a high-precision radiation treatment (CyberKnife SBRT) for prostate cancer that is still within the prostate. It aims to see if a very short course of radiation works well with fewer side effects.
This trial tests a very focused type of radiation (SBRT) for people with pancreatic cancer that hasn't spread to other organs but can't be removed with surgery. It may be an option if you are medically unable to have surgery or choose not to.
This trial tests whether giving targeted radiation (SBRT) followed by an experimental immunotherapy drug injected directly into the tumor is safe for people with locally advanced pancreatic cancer. It aims to shrink the tumor and help your immune system fight it.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
Hear when a new Pancreas Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.